Vytrus Biotech, S.A. (FRA:V5P)

Market Cap	69.22M +321.1%
Revenue (ttm)	8.09M +54.4%
Net Income	1.95M +180.2%
EPS	n/a
Shares Out	n/a
PE Ratio	35.46
Forward PE	25.84
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	13
Open	8.85
Previous Close	8.55
Day's Range	8.40 - 8.85
52-Week Range	1.98 - 10.50
Beta	n/a
RSI	57.50
Earnings Date	Mar 25, 2026

About Vytrus Biotech

Vytrus Biotech, S.A. develops, produces, and sells active ingredients from plant stem cells in Spain and internationally. The company offers Clarivine that activates skin’s regeneration processes; Quora Noni biomics for rejuvenating the skin microbiota; Deobiome Noni, a prebiotic deodorant to reduce the generation of body odour; Sarcoslim Re-Shape, an active ingredient to reduce fat on tissue; Capilia Longa that improves density in hair, eyebrows, and eyelashes; and Luminia Granatum that brightens skin, whitens dark spots, evens skin tone, and ...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2009
• Employees: 37
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: V5P

Financial Performance

In 2024, Vytrus Biotech's revenue was 6.09 million, an increase of 29.51% compared to the previous year's 4.70 million. Earnings were 1.02 million, an increase of 87.36%.